Longitudinal Analysis of Raltegravir Susceptibility and Integrase Replication Capacity of Human Immunodeficiency Virus Type 1 during Virologic Failure-Reference-Cited by-同舟云学术

Longitudinal Analysis of Raltegravir Susceptibility and Integrase Replication Capacity of Human Immunodeficiency Virus Type 1 during Virologic Failure

Published:2009-10 Issue:10 Volume:53 Page:4522-4524
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Fransen Signe¹,Karmochkine Marina²,Huang Wei¹,Weiss Laurence²³,Petropoulos Christos J.¹,Charpentier Charlotte³⁴

Affiliation:

1. Monogram Biosciences, South San Francisco, California

2. Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service d'Immunologie Clinique, Paris, France

3. Université Paris Descartes, Paris, France

4. Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Laboratoire de Virologie, Paris, France

Abstract

ABSTRACT We characterized the raltegravir (RAL) susceptibility and the integrase (IN)-mediated replication capacity (RC) of RAL-resistant human immunodeficiency virus type 1 from two patients experiencing virologic failure during continuous RAL salvage therapy. The following two distinct outcomes were observed: (i) the selective outgrowth of virus with high-level RAL resistance and high IN-mediated RC leading to significant viral load rebound and (ii) the selection of virus with a slight reduction in RAL susceptibility and low IN-mediated RC resulting in sustained low-level viremia.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00651-09

Reference9 articles.

1. Clonal analysis of raltegravir-resistant patterns including mutations at positions 143 and 155 in the HIV-1 integrase. 2009

2. Charpentier, C., M. Karmochkine, D. Laureillard, P. Tisserand, L. Bélec, L. Weiss, A. Si-Mohamed, and C. Piketty. 2008. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med.9:765-770.

3. Cooper, D. A., R. T. Steigbigel, J. M. Gatell, J. K. Rockstroh, C. Katlama, P. Yeni, A. Lazzarin, B. Clotet, P. N. Kumar, J. E. Eron, M. Schechter, M. Markowitz, M. R. Loutfy, J. L. Lennox, J. Zhao, J. Chen, D. M. Ryan, R. R. Rhodes, J. A. Killar, L. R. Gilde, K. M. Strohmaier, A. R. Meibohm, M. D. Miller, D. J. Hazuda, M. L. Nessly, M. J. DiNubile, R. D. Isaacs, H. Teppler, B. Y. Nguyen, and BENCHMRK Study Teams. 2008. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med.359:355-365.

4. Performance characteristics and validation of the PhenoSense HIV integrase assay. 2008

5. Fransen, S., S. Gupta, R. M. Danovich, D. Hazuda, M. D. Miller, M. Witmer, C. J. Petropoulos, N. T. Parkin, and W. Huang. 2008. Loss of raltegravir susceptibility in treated patients is conferred by multiple non-overlapping genetic pathways. Antivir. Ther.13(Suppl. 3):A9.

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study;Antimicrobial Agents and Chemotherapy;2022-01-18

2. Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs;Viruses;2021-01-29

3. Raltegravir-Induced Adaptations of the HIV-1 Integrase: Analysis of Structure, Variability, and Mutation Co-occurrence;Frontiers in Microbiology;2019-09-03

4. Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice;Journal of Antimicrobial Chemotherapy;2017-06-13

5. Viral Phenotypic Resistance Assays;Antimicrobial Drug Resistance;2017